Medicare Enrolled

Dr. James Mackey, MD

Medical Oncology · Southlake, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
431 E STATE HIGHWAY 114 STE 470, Southlake, TX 76092
8174160202
In practice since 2006 (19 years)
NPI: 1356388870 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mackey from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mackey? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mackey

Dr. James Mackey is a medical oncology in Southlake, TX, with 19 years in practice. Based on federal Medicare data, Dr. Mackey performed 311 Medicare services across 243 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mackey received a total of $311,683 from 93 pharmaceutical and/or device companies across 1073 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mackey is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ 311 Medicare services$ $311,683 industry payments

Medicare Practice Summary

Medicare Utilization ↗
311
Medicare services
Bottom 27% in TX for medical oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
243
Unique beneficiaries
$67
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~16 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)78$75$222
Office visit, established patient (20-29 min)76$43$276
Office visit, established patient (10-19 min)53$31$183
Hospital follow-up visit, moderate complexity33$62$203
Office visit, established patient, complex (40-54 min)21$112$324
Initial hospital admission, moderate complexity20$102$317
New patient office visit, complex (60-74 min)17$142$460
New patient office visit (45-59 min)13$89$372
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$311,683
Total received (2018-2024)
Avg $44,526/year across 7 years
Top 6% in TX for medical oncology
93
Companies
1,073
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$279,311 (89.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$19,399 (6.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,335 (4.0%)
Other
Charitable contributions, space rental, and other categories
$637 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$428
2023
$8,113
2022
$9,094
2021
$99,968
2020
$26,647
2019
$120,163
2018
$47,269

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$256,443
Celgene Corporation
$19,688
Heron Therapeutics, Inc.
$12,856
Gilead Sciences, Inc.
$5,310
Pharmacosmos Therapeutics Inc.
$3,392
Amgen Inc.
$1,283
E.R. Squibb & Sons, L.L.C.
$1,093
Novartis Pharmaceuticals Corporation
$1,057
AstraZeneca Pharmaceuticals LP
$779
Seagen Inc.
$651
PFIZER INC.
$647
GENZYME CORPORATION
$547
Genentech USA, Inc.
$523
Lilly USA, LLC
$506
Janssen Biotech, Inc.
$439
Pharmacyclics LLC, An AbbVie Company
$412
Astellas Pharma US Inc
$341
Merck Sharp & Dohme Corporation
$334
Rigel Pharmaceuticals, Inc.
$322
Takeda Pharmaceuticals U.S.A., Inc.
$307
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Incyte Corporation
$279
Boehringer Ingelheim Pharmaceuticals, Inc.
$248
GlaxoSmithKline, LLC.
$205
Dendreon Pharmaceuticals LLC
$197
Merck Sharp & Dohme LLC
$177
ABBVIE INC.
$148
Ipsen Biopharmaceuticals, Inc
$147
Regeneron Healthcare Solutions, Inc.
$142
Seattle Genetics, Inc.
$135
AVEO Pharmaceuticals, Inc.
$132
Bayer HealthCare Pharmaceuticals Inc.
$125
Exelixis Inc.
$121
SANOFI-AVENTIS U.S. LLC
$120
BeiGene USA, Inc.
$114
Verastem, Inc.
$112
TESARO, Inc.
$109
EISAI INC.
$101
SEAGEN INC.
$99
Taiho Oncology, Inc.
$87
Dova Pharmaceuticals
$86
AbbVie, Inc.
$84
Teva Pharmaceuticals USA, Inc.
$79
JAZZ PHARMACEUTICALS INC.
$74
Janssen Pharmaceuticals, Inc
$60
CTI BioPharma Corp.
$56
Eisai Inc.
$52
ASD Specialty Healthcare, LLC
$52
Kite Pharma, Inc.
$47
ARRAY BIOPHARMA INC
$46
Lexicon Pharmaceuticals, Inc.
$45
MEDIVATION FIELD SOLUTIONS LLC
$45
Octapharma USA, Inc.
$42
Janssen Scientific Affairs, LLC
$42
Puma Biotechnology, Inc.
$37
Helsinn Therapeutics (U.S.), Inc.
$37
Alexion Pharmaceuticals, Inc.
$36
Coherus Biosciences Inc.
$35
Sirtex Medical Inc
$33
Mirati Therapeutics, Inc.
$31
SOBI, INC
$29
Array BioPharma Inc.
$28
INSYS Therapeutics Inc
$28
Mylan Institutional Inc.
$28
G1 Therapeutics, Inc.
$27
Progenics Pharmaceuticals, Inc.
$27
Adaptive Biotechnologies Corporation
$25
Deciphera Pharmaceuticals Inc.
$25
Bayer Healthcare Pharmaceuticals Inc.
$24
Myriad Genetic Laboratories, Inc.
$22
Epizyme, Inc.,
$21
Pharmacyclics LLC, an AbbVie Company
$20
Foundation Medicine, Inc.
$20
Ferring Pharmaceuticals Inc.
$20
Aveo Pharmaceuticals, Inc.
$20
MorphoSys, US Inc.
$20
Spectrum Pharmaceuticals Inc.
$19
Sobi, Inc
$18
Sun Pharmaceutical Industries Inc.
$18
Fortovia Therapeutics, Inc.
$17
Kyowa Kirin, Inc.
$16
Jazz Pharmaceuticals Inc.
$16
EMD Serono, Inc.
$16
Blue Earth Diagnostics Limited
$16
Novocure Inc.
$16
Agios Pharmaceuticals, Inc.
$15
Karyopharm Therapeutics Inc.
$15
Sysmex Inostics Inc
$15
AMAG Pharmaceuticals, Inc.
$14
Tempus AI, Inc
$14
Novo Nordisk Inc
$13
Tactile Systems Technology Inc
$11
Clovis Oncology, Inc.
$3
Top 3 companies account for 92.7% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · Axumin · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRILINTA · BRUKINSA · Braftovi · CABOMETYX · CALQUENCE · CERDELGA · CINVANTI · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELOCTATE · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · Erleada · FERAHEME · FIRMAGON · FLEXITOUCH · FOTIVDA · Fulphila · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · JADENU · JAKAFI · JEVTANA · Jivi · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kovaltry · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · Monoferric · NINLARO · NIVESTYM · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM · ONUREG · OPDIVO · Optune Lua (NovoTTF-200T) · PADCEV · PEMAZYRE · PIQRAY · POTELIGEO · PROLARIS · PROMACTA · PROSTATE CANCER - DISEASE · PROVENGE · PYLARIFY · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Tresiba · Trodelvy · Truxima · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (90%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for medical oncology in TX.

Equivalent to $100,220 per 100 Medicare services performed
Looking for a medical oncology in Southlake?
Compare medical oncologys in the Southlake area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
88
Per 100K population
4.1
County median income
$81,905
Nearest hospital
TEXAS HEALTH HARRIS METHODIST HOSPITAL SOUTHLAKE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mackey is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 6%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mackey experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mackey performed 78 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mackey receive payments from pharmaceutical companies?
Yes. Dr. Mackey received a total of $311,683 from 93 companies across 1,073 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mackey's costs compare to other medical oncologys in Southlake?
Dr. Mackey's average Medicare payment per service is $67. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mackey) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →